Search

Your search keyword '"Chien, Rong‐Nan"' showing total 610 results
Start Over Author "Chien, Rong‐Nan" Publication Type Academic Journals
610 results on '"Chien, Rong‐Nan"'

6. Predictors of hepatic flares after nucleos(t)ide analogue cessation – Results of a global cohort study (RETRACT-B study)

Author

Dongelmans, Edo J., Hirode, Grishma, Hansen, Bettina E., Chen, Chien-Hung, Su, Tung-Hung, Seto, Wai-Kay, Furquim d'Almeida, Arno, van Hees, Stijn, Papatheodoridi, Margarita, Lens, Sabela, Wong, Grace L.H., Brakenhoff, Sylvia M., Chien, Rong-Nan, Feld, Jordan J., Chan, Henry L.Y., Forns, Xavier, Papatheodoridis, George V., Vanwolleghem, Thomas, Yuen, Man-Fung, Hsu, Yao-Chun, Kao, Jia-Horng, Cornberg, Markus, Sonneveld, Milan J., Jeng, Wen-Juei, and Janssen, Harry L.A.

Published
2024
Full Text
View/download PDF

11. Differential Relapse Patterns After Discontinuation of Entecavir vs Tenofovir Disoproxil Fumarate in Chronic Hepatitis B

Author

Choi, Hannah S.J., Hirode, Grishma, Chen, Chien-Hung, Su, Tung-Hung, Seto, Wai-Kay, Van Hees, Stijn, Papatheodoridi, Margarita, Lens, Sabela, Wong, Grace L.H., Brakenhoff, Sylvia M., Chien, Rong-Nan, Feld, Jordan J., Sonneveld, Milan J., Chan, Henry L.Y., Forns, Xavier, Papatheodoridis, George V., Vanwolleghem, Thomas, Yuen, Man-Fung, Hsu, Yao-Chun, Kao, Jia-Horng, Cornberg, Markus, Hansen, Bettina E., Jeng, Wen-Juei, and Janssen, Harry L.A.

Published
2023
Full Text
View/download PDF

12. Metformin reduces hepatocellular carcinoma incidence after successful antiviral therapy in patients with diabetes and chronic hepatitis C in Taiwan

Author

Tsai, Pei-Chien, Kuo, Hsing-Tao, Hung, Chao-Hung, Tseng, Kuo-Chih, Lai, Hsueh-Chou, Peng, Cheng-Yuan, Wang, Jing-Houng, Chen, Jyh-Jou, Lee, Pei-Lun, Chien, Rong-Nan, Yang, Chi-Chieh, Lo, Gin-Ho, Kao, Jia-Horng, Liu, Chun-Jen, Liu, Chen-Hua, Yan, Sheng-Lei, Bair, Ming-Jong, Lin, Chun-Yen, Su, Wei-Wen, Chu, Cheng-Hsin, Chen, Chih-Jen, Tung, Shui-Yi, Tai, Chi-Ming, Lin, Chih-Wen, Lo, Ching-Chu, Cheng, Pin-Nan, Chiu, Yen-Cheng, Wang, Chia-Chi, Cheng, Jin-Shiung, Tsai, Wei-Lun, Lin, Han-Chieh, Huang, Yi-Hsiang, Yeh, Ming-Lun, Huang, Chung-Feng, Hsieh, Meng-Hsuan, Huang, Jee-Fu, Dai, Chia-Yen, Chung, Wan-Long, Chen, Chi-Yi, and Yu, Ming-Lung

Published
2023
Full Text
View/download PDF

15. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study

Author

Blach, Sarah, Terrault, Norah A, Tacke, Frank, Gamkrelidze, Ivane, Craxi, Antonio, Tanaka, Junko, Waked, Imam, Dore, Gregory J, Abbas, Zaigham, Abdallah, Ayat R, Abdulla, Maheeba, Aghemo, Alessio, Aho, Inka, Akarca, Ulus S, Alalwan, Abduljaleel M, Alanko Blomé, Marianne, Al-Busafi, Said A, Aleman, Soo, Alghamdi, Abdullah S, Al-Hamoudi, Waleed K, Aljumah, Abdulrahman A, Al-Naamani, Khalid, Al Serkal, Yousif M, Altraif, Ibrahim H, Anand, Anil C, Anderson, Motswedi, Andersson, Monique I, Athanasakis, Kostas, Baatarkhuu, Oidov, Bakieva, Shokhista R, Ben-Ari, Ziv, Bessone, Fernando, Biondi, Mia J, Bizri, Abdul Rahman N, Brandão-Mello, Carlos E, Brigida, Krestina, Brown, Kimberly A, Brown, Jr, Robert S, Bruggmann, Philip, Brunetto, Maurizia R, Busschots, Dana, Buti, Maria, Butsashvili, Maia, Cabezas, Joaquin, Chae, Chungman, Chaloska Ivanova, Viktorija, Chan, Henry Lik Yuen, Cheinquer, Hugo, Cheng, Kent Jason, Cheon, Myeong-Eun, Chien, Cheng-Hung, Chien, Rong-Nan, Choudhuri, Gourdas, Christensen, Peer Brehm, Chuang, Wan-Long, Chulanov, Vladimir, Cisneros, Laura E, Coco, Barbara, Contreras, Fernando A, Cornberg, Markus, Cramp, Matthew E, Crespo, Javier, Cui, Fuqiang, Cunningham, Chris W, Dagher Abou, Lucy, Dalgard, Olav, Dao, Doan Y, De Ledinghen, Victor, Derbala, Moutaz F, Deuba, Keshab, Dhindsa, Karan, Djauzi, Samsuridjal, Drazilova, Sylvia, Duberg, Ann-Sofi, Elbadri, Mohammed, El-Sayed, Manal H, Esmat, Gamal, Estes, Chris, Ezzat, Sameera, Färkkilä, Martti A, Ferradini, Laurent, Ferraz, Maria Lucia G, Ferreira, Paulo R A, Filipec Kanizaj, Tajana, Flisiak, Robert, Frankova, Sona, Fung, James, Gamkrelidze, Amiran, Gane, Edward, Garcia, Virginia, García-Samaniego, Javier, Gemilyan, Manik, Genov, Jordan, Gheorghe, Liliana S, Gholam, Pierre M, Goldis, Adrian, Gottfredsson, Magnus, Gray, Richard T, Grebely, Jason, Gschwantler, Michael, Hajarizadeh, Behzad, Hamid, Saeed S, Hamoudi, Waseem, Hatzakis, Angelos, Hellard, Margaret E, Himatt, Sayed, Hofer, Harald, Hrstic, Irena, Hunyady, Bela, Husa, Petr, Husic-Selimovic, Azra, Jafri, Wasim S M, Janicko, Martin, Janjua, Naveed, Jarcuska, Peter, Jaroszewicz, Jerzy, Jerkeman, Anna, Jeruma, Agita, Jia, Jidong, Jonasson, Jon G, Kåberg, Martin, Kaita, Kelly D E, Kaliaskarova, Kulpash S, Kao, Jia-Horng, Kasymov, Omor T, Kelly-Hanku, Angela, Khamis, Faryal, Khamis, Jawad, Khan, Aamir G, Khandu, Lekey, Khoudri, Ibtissam, Kielland, Knut B, Kim, Do Young, Kodjoh, Nicolas, Kondili, Loreta A, Krajden, Mel, Krarup, Henrik Bygum, Kristian, Pavol, Kwon, Jisoo A, Lagging, Martin, Laleman, Wim, Lao, Wai Cheung, Lavanchy, Daniel, Lázaro, Pablo, Lazarus, Jeffrey V, Lee, Alice U, Lee, Mei-Hsuan, Li, Michael K K, Liakina, Valentina, Lim, Young-Suk, Löve, Arthur, Lukšić, Boris, Machekera, Shepherd Mufudzi, Malu, Abraham O, Marinho, Rui T, Maticic, Mojca, Mekonnen, Hailemichael D, Mendes-Correa, Maria Cássia, Mendez-Sanchez, Nahum, Merat, Shahin, Meshesha, Berhane Redae, Midgard, Håvard, Mills, Mike, Mohamed, Rosmawati, Mooneyhan, Ellen, Moreno, Christophe, Muljono, David H, Müllhaupt, Beat, Musabaev, Erkin, Muyldermans, Gaëtan, Nartey, Yvonne Ayerki, Naveira, Marcelo C M, Negro, Francesco, Nersesov, Alexander V, Njouom, Richard, Ntagirabiri, Rénovat, Nurmatov, Zuridin S, Obekpa, Solomon A, Oguche, Stephen, Olafsson, Sigurdur, Ong, Janus P, Opare-Sem, Ohene K, Orrego, Mauricio, Øvrehus, Anne L, Pan, Calvin Q, Papatheodoridis, George V, Peck-Radosavljevic, Markus, Pessoa, Mário G, Phillips, Richard O, Pimenov, Nikolay, Plaseska-Karanfilska, Dijana, Prabdial-Sing, Nishi N, Puri, Pankaj, Qureshi, Huma, Rahman, Aninda, Ramji, Alnoor, Razavi-Shearer, Devin M, Razavi-Shearer, Kathryn, Ridruejo, Ezequiel, Ríos-Hincapié, Cielo Y, Rizvi, S M Shahriar, Robaeys, Geert K M M, Roberts, Lewis R, Roberts, Stuart K, Ryder, Stephen D, Sadirova, Shakhlo, Saeed, Umar, Safadi, Rifaat, Sagalova, Olga, Said, Sanaa S, Salupere, Riina, Sanai, Faisal M, Sanchez-Avila, Juan F, Saraswat, Vivek A, Sarrazin, Christoph, Sarybayeva, Gulya, Seguin-Devaux, Carole, Sharara, Ala I, Sheikh, Mahdi, Shewaye, Abate B, Sievert, William, Simojoki, Kaarlo, Simonova, Marieta Y, Sonderup, Mark W, Spearman, C Wendy, Sperl, Jan, Stauber, Rudolf E, Stedman, Catherine A M, Su, Tung-Hung, Suleiman, Anita, Sypsa, Vana, Tamayo Antabak, Natalia, Tan, Soek-Siam, Tergast, Tammo L, Thurairajah, Prem H, Tolmane, Ieva, Tomasiewicz, Krzysztof, Tsereteli, Maia, Uzochukwu, Benjamin S C, Van De Vijver, David A M C, Van Santen, Daniela K, Van Vlierberghe, Hans, Van Welzen, Berend, Vanwolleghem, Thomas, Vélez-Möller, Patricia, Villamil, Federico, Vince, Adriana, Waheed, Yasir, Weis, Nina, Wong, Vincent W-S, Yaghi, Cesar G, Yesmembetov, Kakharman, Yosry, Ayman, Yuen, Man-Fung, Yunihastuti, Evy, Zeuzem, Stefan, Zuckerman, Eli, and Razavi, Homie A

Published
2022
Full Text
View/download PDF

16. Off-Therapy Response After Nucleos(t)ide Analogue Withdrawal in Patients With Chronic Hepatitis B: An International, Multicenter, Multiethnic Cohort (RETRACT-B Study)

Author

Hirode, Grishma, Choi, Hannah S.J., Chen, Chien-Hung, Su, Tung-Hung, Seto, Wai-Kay, Van Hees, Stijn, Papatheodoridi, Margarita, Lens, Sabela, Wong, Grace, Brakenhoff, Sylvia M., Chien, Rong-Nan, Feld, Jordan, Sonneveld, Milan J., Chan, Henry L.Y., Forns, Xavier, Papatheodoridis, George V., Vanwolleghem, Thomas, Yuen, Man-Fung, Hsu, Yao-Chun, Kao, Jia-Horng, Cornberg, Markus, Hansen, Bettina E., Jeng, Wen-Juei, and Janssen, Harry L.A.

Published
2022
Full Text
View/download PDF

18. Hepatocellular Carcinoma Incidences and Risk Factors in Hepatitis C Patients: Interferon versus Direct-Acting Agents.

Author

Kao, Yu-Ting, Liu, Yen-Chun, Cheng, Ya-Ting, Wen, Yu-Wen, Hsieh, Yi-Chung, Hsu, Cheng-Er, Su, Chung-Wei, Tai, Jennifer Chia-Hung, Chen, Yi-Cheng, Jeng, Wen-Juei, Lin, Chun-Yen, Chien, Rong-Nan, Tai, Dar-In, and Sheen, I-Shyan

Subjects
CHRONIC hepatitis C, HEPATITIS C virus, PROPENSITY score matching, END of treatment, ANTIVIRAL agents
Abstract

Background: Hepatocellular carcinoma (HCC) remains a significant concern for patients with chronic hepatitis C (HCV), even after achieving a sustained virological response (SVR) with direct-acting antivirals (DAAs) or interferon (IFN)-based therapies. This study compared the risk of HCC in patients with HCV who achieved SVR through the DAA versus IFN regimens. Methods: A retrospective analysis was conducted on 4806 HCV patients, without coinfection nor prior HCC history, treated at the Chang Gung Memorial Hospital, Taiwan (DAA: 2825, IFN: 1981). Kaplan–Meier and Cox regression analyses with propensity score matching (PSM) were used to adjust for baseline differences. Results: DAA-treated patients exhibited a higher incidence of HCC than IFN-treated patients before and after PSM (after PSM: annual: 1% vs. 0.5%; 6-year: 6% vs. 3%, p = 0.01). Both DAA and IFN patients had a decreased HCC incidence during follow-up (>3 vs. <3 years from the end of treatment: DAA: 1.43% vs. 1.00% per year; IFN: 0.47% vs. 0.36% per year, both p < 0.05). HCC incidence was higher in the first three years post-SVR in DAA-treated ACLD patients and then decreased (3.26% vs. 1.39% per year, p < 0.01). In contrast, HCC incidence remained constant in the non-ACLD and IFN-treated groups. Multivariate Cox regression identified age ≥ 60, male sex, BMI, AFP ≥ 6 ng/mL, FIB-4, and ACLD status as independent risk factors for HCC, but antiviral regimens were not an independent factor for HCC. Conclusion: DAA treatment significantly affects HCC risk primarily within three years post-treatment, especially in younger HCV patients with ACLD. HCC incidence was reduced after three years in ACLD patients treated by DAA, but continued surveillance was still necessary. However, patients under 60 without advanced liver disease may require less intensive follow-up. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

19. Hepatitis C-associated late-onset schizophrenia: a nationwide, population-based cohort study

Author

Cheng, Jur-Shan, Hu, Jing-Hong, Chang, Ming-Yu, Lin, Ming-Shyan, Ku, Hsin-Ping, Chien, Rong-Nan, and Chang, Ming-Ling

Subjects
Schizophrenia -- Risk factors, Hepatitis C -- Complications and side effects, Health, Psychology and mental health
Abstract

Background: Whether infection with the hepatitis C virus (HCV) causes schizophrenia--and whether the associated risk reverses after anti-HCV therapy--is unknown; we aimed to investigate these topics. Methods: We conducted a nationwide, population-based cohort study using the Taiwan National Health Insurance Research Database (TNHIRD). A diagnosis of schizophrenia was based on criteria from the International Classification of Diseases, 9th revision (295.xx). Results: From 2003 to 2012, from a total population of 19 298 735, we enrolled 3 propensity-score-matched cohorts (1:2:2): HCV-treated (8931 HCV-infected patients who had received interferon-based therapy for > 6 months); HCV-untreated (17 862); and HCV-uninfected (17 862) from the TNHIRD. Of the total sample (44 655), 82.81% (36 980) were 40 years of age or older. Of the 3 cohorts, the HCV-untreated group had the highest 9-year cumulative incidence of schizophrenia (0.870%, 95% confidence interval [CI] 0.556%-1.311%; p < 0.001); the HCV-treated (0.251%, 95% CI 0.091%-0.599%) and HCV-uninfected (0.118%, 95% CI 0.062%-0.213%) cohorts showed similar cumulative incidence of schizophrenia (p = 0.33). Multivariate Cox analyses showed that HCV positivity (hazard ratio [HR] 3.469, 95% CI 2.168-5.551) was independently associated with the development of schizophrenia. The HCV-untreated cohort also had the highest cumulative incidence of overall mortality (20.799%, 95% CI 18.739%-22.936%; p < 0.001); the HCV-treated (12.518%, 95% CI 8.707%-17.052%) and HCV-uninfected (6.707%, 95% CI 5.533%-8.026%) cohorts showed similar cumulative incidence of mortality (p = 0.12). Limitations: We were unable to determine the precise mechanism of the increased risk of schizophrenia in patients with HCV infection. Conclusion: In a population-based cohort (most aged [greater than or equal to] 40 years), HCV positivity was a potential risk factor for the development of schizophrenia; the HCV-associated risk of schizophrenia might be reversed by interferon-based antiviral therapy., Introduction Hepatitis C virus (HCV) is a human pathogen responsible for acute and chronic liver disease that infects an estimated 150 million people worldwide, (1) with an estimated global prevalence [...]

Published
2021
Full Text
View/download PDF

20. Long-term outcome of liver complications in patients with chronic HBV/HCV co-infection after antiviral therapy: a real-world nationwide study on Taiwanese Chronic Hepatitis C Cohort (T-COACH)

Author

Yeh, Ming-Lun, Hung, Chao-Hung, Tseng, Kuo-Chih, Lai, Hsueh-Chou, Chen, Chi-Yi, Kuo, Hsing-Tao, Wang, Jing-Houng, Chen, Jyh-Jou, Lee, Pei-Lun, Chien, Rong-Nan, Yang, Chi-Chieh, Lo, Gin-Ho, Tai, Chi‐Ming, Lin, Chih-Wen, Kao, Jia-Horng, Liu, Chen-Hua, Yan, Sheng-Lei, Bair, Ming-Jong, Lin, Chun-Yen, Su, Wei-Wen, Chu, Cheng-Hsin, Chen, Chih-Jen, Tung, Shui-Yi, Lo, Ching-Chu, Cheng, Pin-Nan, Chiu, Yen-Cheng, Wang, Chia-Chi, Cheng, Jin-Shiung, Tsai, Wei-Lun, Lin, Han-Chieh, Huang, Yi-Hsiang, Huang, Chung-Feng, Huang, Jee-Fu, Dai, Chia-Yen, Chuang, Wan-Long, Tsai, Pei-Chien, Peng, Cheng-Yuan, Liu, Chun-Jen, and Yu, Ming-Lung

Published
2021
Full Text
View/download PDF

23. Factors associated with treatment responses to pioglitazone in patients with steatotic liver disease: A 3‐year prospective cohort study.

Author

Chang, Ming‐Ling, Tai, Jennifer, Cheng, Jur‐Shan, Chen, Wei‐Ting, Yang, Sien‐Sing, Chiu, Cheng‐Hsun, and Chien, Rong‐Nan

Subjects
ALANINE aminotransferase, PHOSPHOLIPASES, HDL cholesterol, LIVER diseases, PIOGLITAZONE, HEPATIC fibrosis, METHYLENETETRAHYDROFOLATE reductase
Abstract

Aim: The response rate to pioglitazone and the predictive factors for its effects on improving liver biochemistry in patients with steatotic liver disease (SLD) remain elusive, so we aimed to investigate these issues. Methods: A 3‐year prospective cohort study of 126 Taiwanese patients with SLD treated with pioglitazone (15‐30 mg/day) was conducted. Phospholipase domain‐containing protein 3 I148M rs738409, methylenetetrahydrofolate reductase rs1801133, aldehyde dehydrogenase 2 (ALDH2) rs671 and lipoprotein lipase rs10099160 single nucleotide polymorphisms were assessed in the patients. Results: Of 126 patients, 78 (61.9%) were men, and the mean and median ages were 54.3 and 56.5 years, respectively. Pioglitazone responders were defined as those with decreased alanine aminotransferase (ALT) levels at 6 months post‐treatment, and 105 (83.3%) patients were responders. Compared with non‐responders, responders were more frequently women and had higher baseline ALT levels. The proportion of patients with the ALDH2 rs671 GG genotype was lower among responders (38.6% vs. 66.6%, p =.028). Female sex [odds ratio (OR): 4.514, p =.023] and baseline ALT level (OR: 1.015, p =.046; cut‐off level: ≥82 U/L) were associated with pioglitazone response. Among responders, the liver biochemistry and homeostasis model assessment of insulin resistance improved from 6 to 24 months post‐treatment. The total cholesterol levels decreased within 6 months, while increases in high‐density lipoprotein cholesterol levels and decreases in triglyceride levels and fibrosis‐4 scores were noted only at 24 months post‐treatment. The 2‐year cumulative incidences of cardiovascular events, cancers and hepatic events were similar between responders and non‐responders. Conclusions: Regarding liver biochemistry, over 80% of Taiwanese patients with SLD had a pioglitazone response, which was positively associated with female sex and baseline ALT levels. Insulin resistance improved as early as 6 months post‐treatment, while liver fibrosis improvement was not observed until 24 months post‐treatment. The link between the pioglitazone response and the ALDH2 genotype warrants further investigation. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

24. Metformin and statins reduce hepatocellular carcinoma risk in chronic hepatitis C patients with failed antiviral therapy.

Author

Tsai, Pei-Chien, Huang, Chung-Feng, Yeh, Ming-Lun, Hsieh, Meng-Hsuan, Kuo, Hsing-Tao, Hung, Chao-Hung, Tseng, Kuo-Chih, Lai, Hsueh-Chou, Peng, Cheng-Yuan, Wang, Jing-Houng, Chen, Jyh-Jou, Lee, Pei-Lun, Chien, Rong-Nan, Yang, Chi-Chieh, Lo, Gin-Ho, Kao, Jia-Horng, Liu, Chun-Jen, Liu, Chen-Hua, Yan, Sheng-Lei, and Lin, Chun-Yen

Published
2024
Full Text
View/download PDF

25. The Challenge of a Recall Program from a Community-Based Hepatitis C Screening Campaign: The Effectiveness in HCV Microelimination.

Author

Chien, Cheng-Hung, Chou, Tien-Shin, Chen, Li-Wei, Lin, Chih-Lang, Chang, Jia-Jang, Liu, Ching-Jung, Chen, Shuo-Wei, Hu, Ching-Chih, and Chien, Rong-Nan

Subjects
HEPATITIS C virus, HEPATITIS C, HEALTH insurance, MEDICAL screening, CITIES & towns
Abstract

The optimal strategy for the microelimination of HCV within community settings remains ambiguous. We evaluated the percentage of participants who achieved linkage to care (LTC) following the conclusion of a screening campaign and examined the diverse factors influencing LTC among these individuals. The effectiveness of recall intervention for the non-LTC population and its barriers were analyzed. We initiated an HCV patient recall program to identify HCV participants who might not be treated after the HCV screening campaign. The program staff recalled HCV participants who were lost to follow-up via telephone from March 2019 to June 2019. They were informed of HCV treatment's importance, efficacy, availability, and safety. Among 185 participants infected with HCV, 109 (58.9%) obtained LTC. Compared with those who had LTC, those without LTC were older, had lower education levels, were less aware of their HCV infection, less frequently lived in urban areas, and had less health insurance. At the end of the recall program, 125 (67.6%) persons had linkage to care. The proportion of LTC increased by 8.7%. In total, 119 persons had an HCV RNA test, and 82 (68.9%) had viremia. Of the 82 patients with viremia, 78 (95.1%) received antiviral therapy, and 76 (97.4%) achieved a sustained virological response. After a community screening campaign, 59% of participants with anti-HCV-positive tests had LTC. The recall program increased this by 9%. However, 32% of HCV participants still could not be linked to care. Outreach care for non-LTC patients is a method worth trying in order to achieve the microelimination of HCV in rural communities. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

26. Tenofovir alafenamide or tenofovir disoproxil fumarate in pregnancy to prevent HBV transmission: Maternal ALT trajectory and infant outcomes.

Author

Chen, Huey‐Ling, Lee, Chien‐Nan, Chang, Chin‐Hao, Lai, Ming‐Wei, Tsai, Ming‐Chieh, Mu, Shu‐Chi, Liu, Chun‐Jen, Shih, Jin‐Chung, Wen, Wan‐Hsin, Hu, Rui‐Ting, Huang, Chun‐Pin, Hu, Kuang‐Chun, Chen, Chie‐Pein, Lee, Chyi‐Long, Chien, Rong‐Nan, Chang, Kai‐Chi, Hsu, Hong‐Yuan, Lee, Chien‐Chang, Ni, Yen‐Hsuan, and Chang, Mei‐Hwei

Subjects
HEPATITIS B virus, TENOFOVIR, INFANTS, PREGNANCY, PREGNANT women
Abstract

Background: The use of antiviral agents, specifically tenofovir disoproxil fumarate (TDF), in pregnant women to prevent mother‐to‐child HBV transmission is a key step towards hepatitis elimination. However, data on using tenofovir alafenamide (TAF) is insufficient. The frequent occurrence of postpartum ALT flares may impact the clinical implementation. Methods: The maternal and infant outcomes were compared in multi‐centre trials of high viral load HBsAg/HBeAg+ pregnant women receiving TAF or TDF from the third trimester until 2 weeks postpartum with intensive follow‐ups. To explore the dynamic pre‐ and postpartum changes in ALT levels, we used a group‐based trajectory model for analysing data of 332 women from three prospective studies. Results: After treatment, the maternal HBV DNA levels significantly decreased from baseline to delivery: 7.87 ± 0.59 to 3.99 ± 1.07 Log10 IU/mL TAF (n = 78) and 8.30 ± 0.36 to 4.47 ± 0.86 Log10 IU/mL (TDF, n = 53), with viral load reductions of 3.87 versus 3.83 Log10 IU/mL. The HBsAg‐positive rates among 12‐month‐old infants were 1.28% (1/78) versus 1.82% (1/55) respectively (p = 1.00). Of the TAF or TDF‐treated mothers, 25.64% versus 16.98% experienced ALT > 2X ULN, and 11.54% versus 1.89% received extended antiviral treatment. Our model revealed four distinct ALT patterns: stable ALT (87.2%), moderate (8.0%) or marked (2.4%) postpartum flares, or prepartum elevations (2.4%). Conclusions: TAF effectively reduces mother‐to‐child HBV transmission, but prophylaxis failure still occurred in few cases. Postpartum ALT flares are common in women receiving TAF or TDF during pregnancy. Approximately 12.8% of mothers may require extended postpartum antiviral treatment. Clinical trial number: NCT03695029 (ClinicalTrials.gov). [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

29. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials

Author

Gadano, Adrian, Martins, Marcelo, Angus, Peter, Bate, John, Danta, Mark, George, Jacob, Hodge, Alexander, Kontorinis, Nickolas, Roberts, Stuart, Sanagapalli, Santosh, Skoien, Richard, Thompson, Alexander, Zekry, Amany, Stauber, Rudolf, Trauner, Michael, Moreno, Christophe, Reynaert, Hendrik, Verbeke, Len, Silva, Mario Reis Alvares da, Parise, Edison, Oliveira, Claudia Pinto Marques Souza de, Araujo, Roberta Chaves, Martinelli, Ana de Lourdes Candolo, Borman, Meredith, Chandok, Natasha, Elkhashab, Magdy, Fraser, Hughie, Kaita, Kelly, Ma, Mang, Marotta, Paul, Ramji, Alnoor, Tam, Edward, Yoshida, Eric, Swain, Mark, Sebastiani, Giada, Petrunia, Denis, Abergel, Armando, Anty, Rodolphe, Bourlière, Marc, Boursier, Jérôme, Bureau, Christophe, Castera, Laurent, Habersetzer, François, Hézode, Christophe, Ledinghen, Victor De, Leroy, Vincent, Loustaud-Ratti, Véronique, Mathurin, Philippe, Pol, Stanislas, Zoulim, Fabien, Hinrichsen, Holger, Ingiliz, Patrick, Lammert, Frank, Manns, Michael, Schattenberg, Jörn, Schiefke, Ingolf, Trautwein, Christian, Zeuzem, Stefan, Hui, Aric, Li, King-Kong, Wong, Vincent, Acharya, Subrat, Chowdhury, Abhijit, Duseja, Ajay, Kapoor, Dharmesh, Mukewar, Shrikant, Sarin, Shiv, Shah, Samir, Shalimar, Sood, Ajit, Tantry, BV, Ben-Ari, Ziv, Katchman, Helena, Safadi, Rifaat, Veitsman, Ella, Zuckerman, Eli, Brunetto, Maurizia, Lampertico, Pietro, Mangia, Alessandra, Akahane, Takemi, Akuta, Norio, Eguchi, Yuichiro, Fujiyama, Shigetoshi, Genda, Takuya, Hiasa, Yoichi, Ido, Akio, Ikeda, Fusao, Ikegami, Tadashi, Imajo, Kento, Itoh, Yoshito, Iwasa, Motoh, Karino, Yoshiyasu, Kato, Naoya, Kawaguchi, Takumi, Kawanaka, Miwa, Kido, Masahiro, Kobayashi, Tomoo, Kurosaki, Masayuki, Matsuzaki, Yasushi, Mita, Eiji, Mizukoshi, Eishiro, Nakahara, Takashi, Nomura, Hideyuki, Notsumata, Kazuo, Okanoue, Takeshi, Saito, Satoshi, Sakugawa, Hiroshi, Suzuki, Yoshiyuki, Takaguchi, Koichi, Takaki, Akinobu, Takashima, Tomoyuki, Tanaka, Saiyu, Tsuji, Keiji, Ueno, Yoshiyuki, Umemura, Takeji, Uto, Hirofumi, Yamashita, Nobuyuki, Yanase, Mikio, Yatsuhashi, Hiroshi, Yoneda, Masashi, Chan, Wah Kheong, Tan, Soek Siam, Garza, Laura Cisneros, Ladron De Guevara Cetina, Alma, Angeles, Rocio Guadalupe Vargas, Silva, Francisca Martinez, Van Erpecum, Karel, Orr, David, Jabłkowski, Maciej, Jaroszewicz, Jerzy, Ramos, Jose, Ahmed, Taufique, Ang, Tiing, Dan, Yock young, Goh, Boon Bee, Kaliyaperumal, Kalaiyarasi, Yip, Cherng Hann, Baik, Soon Koo, Jang, Byoung Kuk, Jun, Dae Won, Kim, Won, Kim, Hyung Joon, Kim, Ji Hoon, Lee, Kwan Sik, Lee, Chun Kyon, Lim, Young-Suk, Park, Jun Yong, Tak, Won Young, Augustin, Salvador, Perez, Salvador Benlloch, Caballeria, Juan, Luis, Jose, Panero, Calleja, Rodríguez, Jose Carrión, Garcia, Javier Crespo, Samaniego, Javier Garcia, Gibert, Pere Ginès, Prieto, Martin, Gomez, Manuel Romero, Turnes, Juan, Dufour, Jean-Francois, Moriggia, Alberto, Sheen, I-Shyan, Kao, Jia-Horng, Cheng, Pin-Nan, Huang, Jee-Fu, Yang, Sheng-Shun, Su, Wei-Wen, Chen, Chi-Yi, Chien, Rong-Nan, Lo, Gin-Ho, Chu, Chi-Jen, Wang, Horng-Yuan, Hu, Jui-Ting, Huang, Yi Wen, Agarwal, Kosh, Allison, Michael, Anstee, Quentin, Austin, Andrew, Fowell, Andrew, Ch'ng, Chin Lye, Manousou, Pinelopi, Newsome, Philip, Ryder, Stephen, Shankar, Arun, Abdelmalek, Manal, Abrams, Gary, Aguilar, Humberto, Alam, Imtiaz, Alba, Laura, Alkhouri, Naim, Allen, Alina, Aqel, Bashar, Balart, Luis, Barritt, A. Sidney, IV, Behari, Jaideep, Bennett, Michael, Bernstein, David, Bhandari, Bal Raj, Bonacini, Maurizio, Borg, Brian, Brown, Kimberly, Bzowej, Natalie, Caldwell, Stephen, Chami, Tawfik, Coates, Allan, Cueli, Adolfo, Davis, Mitchell, deLemos, Andrew, Desai, Archita, Dunn, Winston, Ferreira, Nelson, Fine, Michael, Firpi-Morell, Roberto, Freedland, Curtis, Freilich, Bradley, Fuchs, Michael, Galambos, Michael, Gallegos-Orozco, Juan, Galler, Greg, Ghali, Maged, Ghalib, Reem, Gill, Satinder, Gillis, Marcum, Gilroy, Richard, Gordon, Stuart, Gunn, Nadege, Halegoua-DeMarzio, Dina, Hassan, Mohamed, Hassanein, Tarek, Herring, Robert, Jr., Hong, John, Huang, Jonathan, Kabler, Heidi, Kayali, Zeid, Knapple, Whitfield, Kolli, Geetha, Kowdley, Kris, Krause, Richard, Lawitz, Eric, Lidofsky, Steven, Lim, Joseph, Lipkis, Donald, Loomba, Rohit, Mahgoub, Amar, Malespin, Miguel, Manch, Richard, Mannis, Steven, Manos, Paul, McDonald, Thomas, McKenzie, Mark, Mena, Edward, Merriman, Raphael, Moehlen, Martin William, Montgomery, Richard, Murphy, Robert, Natarajan, Yamini, Neff, Guy, Noureddin, Mazen, Ortiz-Lasanta, Grisell, Pagadala, Mangesh, Patel, Keyur, Patton, Heather, Peyton, Adam, Pimstone, Neville, Poulos, John, Pound, David, Pyrsopoulos, Nikolaos, Rafiq, Nila, Ravendhran, Natarajan, Ravinuthala, Ravi, Reddy, K. Rajendar, Reindollar, Robert, Reynolds, Justin, Rinella, Mary, Rizvi, Syed, Rockey, Don, Rodriguez-Perez, Federico, Ruane, Peter, Rubin, Raymond, Ryan, Michael, Saeian, Kia, Sanyal, Arun, Sarkar, Souvik, Scanga, Andrew, Schiff, Eugene, Schmidt, Warren, Schneider, Jeffrey, Sepe, Thomas, Shah, Dhiren, Shaikh, Obaid, Shankar, Uday, Sheikh, Aasim, Sheikh, Muhammad, Sherman, Kenneth, Shiffman, Mitchell, Siddique, Asma, Smith, Matthew, Suarez, Rosa, Talal, Andrew, Te, Helen, Tekola, Bezawit, Tetri, Brent, Thuluvath, Paul, Toro, Doris, Torres, Dawn, Trinh, Huy, Trotter, James, Vento, Angel, Vierling, John, Vuppalanchi, Raj, Waters, Michael, Weisberg, Ilan, Wieland, Amanda, Williams, Alonzo, Younes, Ziad, Adams, Leon, Harding, Damian, Hodge, Alex, Kontorinis, Nick, Strasser, Simone, Thompson, Alex, Horsmans, Yves, Steenkiste, Christophe Van, Bailey, Robert, Giard, Jeanne-Marie, Montano-Loza, Aldo, Puglia, Marco, Tsoi, Keith, Larrey, Dominique, Nguyen-Khac, Eric, Ratziu, Vlad, Spengler, Ulrich, Wiegand, Johannes, Hui, Aric Josun, Acharya, Subrat Kumar, Sarin, Shiv Kumar, Tantry, Vishwanath, Braun, Marius, Hazzan, Rawi, Lurie, Yoav, Colombo, Massimo, Fujii, Hideki, Hashimoto, Etsuko, Kato, Masaki, Ogawa, Koji, Takehara, Tetsuo, Tokushige, Katsutoshi, Garza, Laura Esthela Cisneros, Ladrón De Guevara, Alma Laura, Schultz, Michael, Janczewska, Ewa, Toro, Doris H., Jeong, Sook-Hyang, Kim, Yoon Jun, Lee, Jin-Woo, Ang, Tiing Leong, Bee, George Goh Boon, Benlloch, Salvador, Caballería, Juan, Calleja, José Luis, Rodríguez, Jose A. Carrión, Crespo, Javier, Diago, Moises, Fernandez-Rodriguez, Conrado, García-Samaniego, Javier, Ginès, Pere, Romero, Manuel, Dufour, Jean-François, Alazawi, William, Ch'ng, Chin-Lye, Forton, Daniel, Priest, Matthew, Sheridan, David, Ankoma-Sey, Victor, Balakrishnan, Maya, Bambha, Kiran, Barritt, A. Sidney, Bhandari, Bal, Brandman, Danielle, Chang, Charissa, Corey, Kathleen, Feldman, Michael, Gholam, Pierre, Goff, John, Marzio, Dina Halegoua-De, Harrison, Stephen, Hellstern, Paul, Jr., Herring, Robert, Iyer, Rajalakshmi, Jakiche, Antoine, Kohli, Anita, Krok, Karen, Kugelmas, Marcelo, Kumar, Sonal, Lai, Michelle, Mahmoud, Mitchell, Mantry, Parvez, Marsano, Luis, Nguyen, Tuan, Park, James, Patton, Heather M., Pockros, Paul, Reddy, Rajender, Rodriguez, Miguel, Sarles, Harry, Satapathy, Sanjaya, Sedghi, Shahriar, Shah, Nikunj, Sheikh, Muhammad Yasin, Sigal, Samuel, Stanca, Carmen, Steinbook, Michael, Szabo, Gyongyi, Terrault, Norah, Tong, Myron, Victor, David, Zervos, Xaralambos, Harrison, Stephen A., Wong, Vincent Wai-Sun, Caldwell, Stephen H., Shiffman, Mitchell L., Camargo, Marianne, Li, Georgia, Kersey, Kathryn, Jia, Catherine, Zhu, Yanni, Djedjos, C. Stephen, Subramanian, G. Mani, Myers, Robert P., Anstee, Quentin M., Romero-Gomez, Manuel, Goodman, Zachary, Lawitz, Eric J., and Younossi, Zobair

Published
2020
Full Text
View/download PDF

38. Evolutionary relationship between antimitochondrial antibody positivity and primary biliary cholangitis in Taiwan: a 16-year hospital cohort study.

Author

Chang, Ming-Ling, Cheng, Jur-Shan, Le, Puo-Hsien, Chen, Wei-Ting, Ku, Hsin-Ping, and Chien, Rong-Nan

Subjects
CHOLANGITIS, CHRONIC hepatitis B, CHRONIC hepatitis C, VIRAL hepatitis, COHORT analysis, ALKALINE phosphatase
Abstract

Background: How antimitochondrial antibody (AMA)-positive patients evolve to have primary biliary cholangitis (PBC) in viral hepatitis–endemic areas is unknown. Objectives: We aimed to investigate this evolution in Taiwan. Design/methods: A 16-year medical center-based cohort study of 2,095,628 subjects was conducted in Taiwan, an Asian country endemic to viral hepatitis. AMA-positive subjects were those with positive AMA with alkaline phosphatase (ALP) ⩽1.5 times the upper limit of normal (ULN), and PBC was defined as positive AMA with ALP >1.5 × ULN. Results: AMA-positive subjects had a lower average age- and sex-adjusted prevalence than PBC patients (4.68/105 versus 11.61/105, p = 0.0002), but their incidence was comparable (0.99/105 versus 1.12/105, p = 0.36). The former group had a borderline significantly lower mean age (56.59 years versus 58.10 years, p = 0.06) and a lower female-to-male ratio (2.85:1 versus 5.44:1, p < 0.0001). Both AMA-positive subjects (prevalence change: 20.0%, p < 0.01; incidence change: −9.2%, p < 0.01) and PBC patients (prevalence change: 14.6%, p < 0.01; incidence change: −4.7%, p < 0.01) prevalence rate increased but the incidence rate decreased. Among the 423 AMA-positive subjects, 77 (18.2%) developed PBC, for a mean duration of 1.757 years. Compared with AMA-positive subjects, PBC patients had similar concurrent chronic hepatitis B (CHB) rates (2.7% versus 4.3%, p = 0.197) but lower chronic hepatitis C (CHC) rates (3.69% versus 15.60%, p < 0.01). Conclusion: PBC was more prevalent than AMA-positive subjects, and PBC patients had a higher female-to-male ratio than AMA-positive subjects, of whom 18.2% developed PBC (mean lag: 1.757 years). Upward trends in prevalence rates and downward trends in incidence rates were noted for both AMA-positive subjects and PBC. CHB was rare, CHC was more prevalent among PBC patients than the general population, and CHC was less prevalent among PBC than among AMA-positive subjects. Plain language summary: Evolutionary relationship between AMA positivity and PBC in Taiwan PBC was more prevalent than AMA-positive subjects, and PBC patients had a higher female-to-male ratio than AMA-positive subjects, of whom 18.2% developed PBC (mean lag: 1.757 years). Upward trends in prevalence rates and downward trends in incidence rates were noted for both AMA-positive subjects and PBC. CHB was rare, CHC was more prevalent among PBC patients than the general population, and CHC was less prevalent among PBC than among AMA-positive subjects. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

39. Higher end‐of‐treatment HBsAg levels is associated with later onset but not severe relapse in HBeAg‐negative chronic hepatitis B patients stopping antivirals.

Author

Liu, Yen‐Chun, Jeng, Wen‐Juei, Peng, Chien‐Wei, Chien, Rong‐Nan, and Liaw, Yun‐Fan

Subjects
CHRONIC hepatitis B, HEPATITIS associated antigen, END of treatment, PEARSON correlation (Statistics), DISEASE relapse, ANTIVIRAL agents
Abstract

Summary: Background: Quantitative hepatitis B surface antigen (qHBsAg) level at end‐of‐treatment (EOT) predict clinical relapse (CR) after nucleos(t)ide analogues (Nuc) in chronic hepatitis B(CHB) patients. It is unclear if higher EOT qHBsAg leads to earlier onset or more severe off‐Nuc CR. Aim: This large cohort study investigates the association between EOT qHBsAg and CR onset/severity. Methods: This study enrolled HBeAg‐negative CHB patients who had achieved undetectable HBV DNA for over 1 year after receiving Nuc therapy before discontinuation. The EOT qHBsAg level was categorised into three groups: <100, 100–999, ≥1000 IU/mL. The study assessed the predictability of qHBsAg levels for CR, and analysed and compared the incidence, time to onset and severity of CR among these three groups. Results: Patients with higher EOT qHBsAg showed a higher incidence of CR (≥1000, 100–999, <100 IU/mL: 73%, 65%, and 38%, p < 0.01) but a later onset of CR (median time to CR: 35, 33 and 27 weeks, p < 0.01). The predictabilities of EOT qHBsAg for CR were greater in patients aged <50‐year‐old or with genotype C than in those aged ≥50‐year‐old or with genotype B. There's no correlation between EOT qHBsAg level and ALT folds at CR (Pearson correlation coefficient: r = −0.03, p = 0.35). EOT qHBsAg was neither a predictor for severe hepatitis flare nor a predictor for hepatic decompensation. Conclusions: Predictability using EOT qHBsAg levels for CR differed in subgroups of age and genotypes. Higher EOT qHBsAg levels correlate with higher incidence but later onset of CR. No correlation between EOT qHBsAg and relapse severity was observed. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

42. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study

Author

Razavi-Shearer, Devin, Gamkrelidze, Ivane, Nguyen, Mindie H, Chen, Ding-Shinn, Van Damme, Pierre, Abbas, Zaigham, Abdulla, Maheeba, Abou Rached, Antoine, Adda, Danjuma, Aho, Inka, Akarca, Ulus, Hasan, Fuad, Al Lawati, Faryal, Al Naamani, Khalid, Al-Ashgar, Hamad Ibrahim, Alavian, Seyed M, Alawadhi, Sameer, Albillos, Agustin, Al-Busafi, Said A, Aleman, Soo, Alfaleh, Faleh Z, Aljumah, Abdulrahman A, Anand, Anil C, Anh, Nguyen Thu, Arends, Joop E, Arkkila, Perttu, Athanasakis, Kostas, Bane, Abate, Ben-Ari, Ziv, Berg, Thomas, Bizri, Abdul R, Blach, Sarah, Brandão Mello, Carlos E, Brandon, Samantha M, Bright, Bisi, Bruggmann, Philip, Brunetto, Maurizia, Buti, Maria, Chan, Henry L Y, Chaudhry, Asad, Chien, Rong-Nan, Choi, Moon S, Christensen, Peer B, Chuang, Wan-Long, Chulanov, Vladimir, Clausen, Mette R, Colombo, Massimo, Cornberg, Markus, Cowie, Benjamin, Craxi, Antonio, Croes, Esther A, Cuellar, Diego Alberto, Cunningham, Chris, Desalegn, Hailemichael, Drazilova, Sylvia, Duberg, Ann-Sofi, Egeonu, Steve S, El-Sayed, Manal H, Estes, Chris, Falconer, Karolin, Ferraz, Maria L G, Ferreira, Paulo R, Flisiak, Robert, Frankova, Sona, Gaeta, Giovanni B, García-Samaniego, Javier, Genov, Jordan, Gerstoft, Jan, Goldis, Adrian, Gountas, Ilias, Gray, Richard, Guimarães Pessôa, Mário, Hajarizadeh, Behzad, Hatzakis, Angelos, Hézode, Christophe, Himatt, Sayed M, Hoepelman, Andy, Hrstic, Irena, Hui, Yee-Tak T, Husa, Petr, Jahis, Rohani, Janjua, Naveed Z, Jarčuška, Peter, Jaroszewicz, Jerzy, Kaymakoglu, Sabahattin, Kershenobich, David, Kondili, Loreta A, Konysbekova, Aliya, Krajden, Mel, Kristian, Pavol, Laleman, Wim, Lao, Wai-cheung C, Layden, Jen, Lazarus, Jeffrey V, Lee, Mei-Hsuan, Liakina, Valentina, Lim, Young-Suk S, Loo, Ching-kong K, Lukšić, Boris, Malekzadeh, Reza, Malu, Abraham O, Mamatkulov, Adkhamjon, Manns, Michael, Marinho, Rui T, Maticic, Mojca, Mauss, Stefan, Memon, Muhammad S, Mendes Correa, Maria C, Mendez-Sanchez, Nahum, Merat, Shahin, Metwally, Ammal M, Mohamed, Rosmawati, Mokhbat, Jacques E, Moreno, Christophe, Mossong, Joel, Mourad, Fadi H, Müllhaupt, Beat, Murphy, Kimberly, Musabaev, Erkin, Nawaz, Arif, Nde, Helen M, Negro, Francesco, Nersesov, Alexander, Nguyen, Van Thi Thuy, Njouom, Richard, Ntagirabiri, Renovat, Nurmatov, Zuridin, Obekpa, Solomon, Ocama, Ponsiano, Oguche, Stephen, Omede, Ogu, Omuemu, Casimir, Opare-Sem, Ohene, Opio, Christopher K, Örmeci, Necati, Papatheodoridis, George, Pasini, Ken, Pimenov, Nikolay, Poustchi, Hossein, Quang, Trân D, Qureshi, Huma, Ramji, Alnoor, Razavi-Shearer, Kathryn, Redae, Berhane, Reesink, Henk W, Rios, Cielo Yaneth, Rjaskova, Gabriela, Robbins, Sarah, Roberts, Lewis R, Roberts, Stuart K, Ryder, Stephen D, Safadi, Rifaat, Sagalova, Olga, Salupere, Riina, Sanai, Faisal M, Sanchez-Avila, Juan F, Saraswat, Vivek, Sarrazin, Christoph, Schmelzer, Jonathan D, Schréter, Ivan, Scott, Julia, Seguin-Devaux, Carole, Shah, Samir R, Sharara, Ala I, Sharma, Manik, Shiha, Gamal E, Shin, Tesia, Sievert, William, Sperl, Jan, Stärkel, Peter, Stedman, Catherine, Sypsa, Vana, Tacke, Frank, Tan, Soek S, Tanaka, Junko, Tomasiewicz, Krzysztof, Urbanek, Petr, van der Meer, Adriaan J, Van Vlierberghe, Hans, Vella, Stefano, Vince, Adriana, Waheed, Yasir, Waked, Imam, Walsh, Nicholas, Weis, Nina, Wong, Vincent W, Woodring, Joseph, Yaghi, Cesar, Yang, Hwai-I, Yang, Chung-Lin, Yesmembetov, Kakharman, Yosry, Ayman, Yuen, Man-Fung, Yusuf, Muhammed Aasim M, Zeuzem, Stefan, and Razavi, Homie

Published
2018
Full Text
View/download PDF

43. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study

Author

Blach, Sarah, Zeuzem, Stefan, Manns, Michael, Altraif, Ibrahim, Duberg, Ann-Sofi, Muljono, David H, Waked, Imam, Alavian, Seyed M, Lee, Mei-Hsuan, Negro, Francesco, Abaalkhail, Faisal, Abdou, Ahmed, Abdulla, Maheeba, Rached, Antoine Abou, Aho, Inka, Akarca, Ulus, Al Ghazzawi, Imad, Al Kaabi, Saad, Al Lawati, Faryal, Al Namaani, Khalid, Al Serkal, Youssif, Al-Busafi, Said A, Al-Dabal, Layla, Aleman, Soo, Alghamdi, Abdullah S, Aljumah, Abdulrahman A, Al-Romaihi, Hamad E, Andersson, Monique I, Arendt, Vic, Arkkila, Perttu, Assiri, Abdullah M, Baatarkhuu, Oidov, Bane, Abate, Ben-Ari, Ziv, Bergin, Colm, Bessone, Fernando, Bihl, Florian, Bizri, Abdul R, Blachier, Martin, Blasco, Antonio J, Mello, Carlos E Brandão, Bruggmann, Philip, Brunton, Cheryl R, Calinas, Filipe, Chan, Henry L Y, Chaudhry, Asad, Cheinquer, Hugo, Chen, Chien-Jen, Chien, Rong-Nan, Choi, Moon Seok, Christensen, Peer B, Chuang, Wan-Long, Chulanov, Vladimir, Cisneros, Laura, Clausen, Mette R, Cramp, Matthew E, Craxi, Antonio, Croes, Esther A, Dalgard, Olav, Daruich, Jorge R, de Ledinghen, Victor, Dore, Gregory J, El-Sayed, Manal H, Ergör, Gul, Esmat, Gamal, Estes, Chris, Falconer, Karolin, Farag, Elmoubashar, Ferraz, Maria L G, Ferreira, Paulo R, Flisiak, Robert, Frankova, Sona, Gamkrelidze, Ivane, Gane, Ed, García-Samaniego, Javier, Khan, Amir Ghafoor, Gountas, Ilias, Goldis, Adrian, Gottfredsson, Magnús, Grebely, Jason, Gschwantler, Michael, Pessôa, Mário Guimarães, Gunter, Jessie, Hajarizadeh, Behzad, Hajelssedig, Omer, Hamid, Saeed, Hamoudi, Waseem, Hatzakis, Angelos, Himatt, Sayed M, Hofer, Harald, Hrstic, Irena, Hui, Yee-Tak, Hunyady, Bela, Idilman, Ramazan, Jafri, Wasim, Jahis, Rohani, Janjua, Naveed Z, Jarčuška, Peter, Jeruma, Agita, Jonasson, Jón G, Kamel, Yasser, Kao, Jia-Horng, Kaymakoglu, Sabahattin, Kershenobich, David, Khamis, Jawad, Kim, Young S, Kondili, Loreta, Koutoubi, Zaher, Krajden, Mel, Krarup, Henrik, Lai, Moon-sing, Laleman, Wim, Lao, Wai-cheung, Lavanchy, Daniel, Lázaro, Pablo, Leleu, Henri, Lesi, Olufunmilayo, Lesmana, Laurentius A, Li, Michael, Liakina, Valentina, Lim, Young-Suk, Luksic, Boris, Mahomed, Adam, Maimets, Matti, Makara, Mihály, Malu, Abraham O, Marinho, Rui T, Marotta, Paul, Mauss, Stefan, Memon, Muhammad S, Correa, Maria C Mendes, Mendez-Sanchez, Nahum, Merat, Shahin, Metwally, Ammal M, Mohamed, Rosmawati, Moreno, Christophe, Mourad, Fadi H, Müllhaupt, Beat, Murphy, Kimberly, Nde, Helen, Njouom, Richard, Nonkovic, Diana, Norris, Suzanne, Obekpa, Solomon, Oguche, Stephen, Olafsson, Sigurður, Oltman, Marian, Omede, Ogu, Omuemu, Casimir, Opare-Sem, Ohene, Øvrehus, Anne L H, Owusu-Ofori, Shirley, Oyunsuren, Tsendsuren S, Papatheodoridis, George, Pasini, Ken, Peltekian, Kevork M, Phillips, Richard O, Pimenov, Nikolay, Poustchi, Hossein, Prabdial-Sing, Nishi, Qureshi, Huma, Ramji, Alnoor, Razavi-Shearer, Devin, Razavi-Shearer, Kathryn, Redae, Berhane, Reesink, Henk W, Ridruejo, Ezequiel, Robbins, Sarah, Roberts, Lewis R, Roberts, Stuart K, Rosenberg, William M, Roudot-Thoraval, Françoise, Ryder, Stephen D, Safadi, Rifaat, Sagalova, Olga, Salupere, Riina, Sanai, Faisal M, Avila, Juan F Sanchez, Saraswat, Vivek, Sarmento-Castro, Rui, Sarrazin, Christoph, Schmelzer, Jonathan D, Schréter, Ivan, Seguin-Devaux, Carole, Shah, Samir R, Sharara, Ala I, Sharma, Manik, Shevaldin, Anatoly, Shiha, Gamal E, Sievert, William, Sonderup, Mark, Souliotis, Kyriakos, Speiciene, Danute, Sperl, Jan, Stärkel, Peter, Stauber, Rudolf E, Stedman, Catherine, Struck, Daniel, Su, Tung-Hung, Sypsa, Vana, Tan, Soek-Siam, Tanaka, Junko, Thompson, Alexander J, Tolmane, Ieva, Tomasiewicz, Krzysztof, Valantinas, Jonas, Van Damme, Pierre, van der Meer, Adriaan J, van Thiel, Ingo, Van Vlierberghe, Hans, Vince, Adriana, Vogel, Wolfgang, Wedemeyer, Heiner, Weis, Nina, Wong, Vincent WS, Yaghi, Cesar, Yosry, Ayman, Yuen, Man-fung, Yunihastuti, Evy, Yusuf, Aasim, Zuckerman, Eli, and Razavi, Homie

Published
2017
Full Text
View/download PDF

46. Sustained virological response to hepatitis C therapy does not decrease the incidence of systemic lupus erythematosus or rheumatoid arthritis

Author

Hsu, Wei-Fan, Chen, Chi-Yi, Tseng, Kuo-Chih, Lai, Hsueh-Chou, Kuo, Hsing-Tao, Hung, Chao-Hung, Tung, Shui-Yi, Wang, Jing-Houng, Chen, Jyh-Jou, Lee, Pei-Lun, Chien, Rong-Nan, Lin, Chun-Yen, Yang, Chi-Chieh, Lo, Gin-Ho, Tai, Chi-Ming, Lin, Chih-Wen, Kao, Jia-Horng, Liu, Chun-Jen, Liu, Chen-Hua, Yan, Sheng-Lei, Bair, Ming-Jong, Su, Wei-Wen, Chu, Cheng-Hsin, Chen, Chih-Jen, Lo, Ching-Chu, Cheng, Pin-Nan, Chiu, Yen-Cheng, Wang, Chia-Chi, Cheng, Jin-Shiung, Tsai, Wei-Lun, Lin, Han-Chieh, Huang, Yi-Hsiang, Tsai, Pei-Chien, Huang, Jee-Fu, Dai, Chia-Yen, Chuang, Wan-Long, Yu, Ming-Lung, and Peng, Cheng-Yuan

Published
2020
Full Text
View/download PDF

48. Association of liver fibrosis with extrahepatic cancer in steatotic liver disease patients with PNPLA3 I148M GG genotype.

Author

Tai, Jennifer, Hsu, Chao‐Wei, Chen, Wei‐Ting, Yang, Sien‐Sing, Chiu, Cheng‐Hsun, Chien, Rong‐Nan, and Chang, Ming‐Ling

Abstract

The impacts of patatin‐like phospholipase domain‐containing protein 3 (PNPLA3) I148M‐rs738409, methylenetetrahydrofolate reductase (MTHFR) Ala222Val‐rs1801133, and aldehyde dehydrogenase 2 (ALDH2) Glu504Lys‐rs671 on the outcomes of Taiwanese patients with steatotic liver disease (SLD) have remained elusive. An 8‐year prospective cohort study of patients with (n = 546) and without (n = 580) SLD (controls) was undertaken in a Taiwanese tertiary care center. The 546 SLD patients comprised 306 (56.0%) men and 240 (44.0%) women with mean ages of 53.3 and 56.4 years, respectively. Compared with the controls, SLD patients had an increased frequency of the PNPLA3 I148M‐rs738409 GG genotype (25.5 vs. 5.9%, p = 0.001). Among the SLD patients, 236 (43.1%) suffered cardiovascular events, 52 (9.5%) showed extrahepatic cancers, 13 (2.38%) experienced hepatic events, including hepatocellular carcinoma (n = 3, 0.5%) and liver cirrhosis (n = 8, 1.47%), and none died. The Fibrosis‐4 (FIB‐4) scores were associated with extrahepatic cancer (hazard ratio [HR] 1.325; 95% confidence interval [CI], 1.038–1.691) and cirrhosis development (HR 1.532; 95% CI, 1.055–2.224), and the PNPLA3 I148M‐rs738409 G allele (β = 0.158, 95% CI, 0.054–0.325) was associated with the FIB‐4 score. Stratified analyses showed that the impact of the FIB‐4 score on extrahepatic cancer development was evident only in SLD patients with the PNPLA3 I148M‐rs738409 GG genotype (HR 1.543; 95% CI, 1.195–1.993) and not in patients with the GC or CC genotype. Moreover, the ALDH2 Glu504Lys‐rs671 G allele had a dose‐dependent effect on alcoholism, and the MTHFR and ALDH2 genotypes were not significantly associated with SLD patient outcomes. In conclusion, special vigilance should be exercised for emerging extrahepatic cancer in SLD patients with the PNPLA3 I148M‐rs738409 GG genotype and high FIB‐4 scores. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

49. Animal naming test is a simple and valid tool for detecting covert hepatic encephalopathy and predicting outcomes in Chinese-speaking regions: a preliminary study.

Author

Huang, Chien-Hao, Yu, Tung-Yang, Tseng, Wei-En Johnny, Huang, Yu-Tung, Chang, Shang-Hung, Hsieh, Sen-Yung, Chien, Rong-Nan, and Amodio, Piero

Subjects
HEPATIC encephalopathy, ANT behavior, ZOOLOGICAL nomenclature, ANIMAL experimentation, RECEIVER operating characteristic curves, MINI-Mental State Examination
Abstract

Hepatic encephalopathy (HE) implies high morbidity and mortality. The assessment of covert HE (CHE) [i.e. minimal HE (MHE) plus grade 1 HE] is often neglected in Taiwan. Therefore, the aim was to investigate the potential of the animal naming test (ANT1 and simplified ANT1 (S-ANT1)) for assessing CHE in Chinese-speaking regions, specifically Taiwan. A prospective cohort study was conducted, comprising 65 cirrhotic patients and 29 healthy controls (relatives of the patients). Patients were followed up every three months and censored after two years or until death. Hospitalization for overt HE (OHE) and mortality were considered. All subjects underwent ANT1, psychometric HE score (PHES), and mini-mental state examination (MMSE). The patients underwent an electroencephalogram (EEG) to detect slowing indicative of MHE. Cut-off values for ANT1 and S-ANT1 were assessed by ROC analysis and Youden's index, considering CHE as a reference. The prognostic values for OHE and OHE-free survival were assessed. Preliminary analysis confirmed that PHES ≤-4 is a good discriminant point for abnormal results. CHE was found in 29 patients: 9 had MHE (PHES ≤ -4 or altered EEG) and 20 had grade 1 HE. ANT1 and S-ANT1 were found to have diagnostic values for CHE: AUC = 0.807, 0.786; cut off: 18 and 19, respectively. ANT1 and S-ANT1 were found to have prognostic value for OHE, number of hospitalization episodes for OHE, and OHE recurrence-free survival. ANT1 shows promise as a tool for CHE detection, quantification, and follow-up in Taiwan and other Chinese-speaking regions. The animal naming test (ANT1) is a simple and valid semantic fluency test that can be easily performed in outpatient or bedside settings in one minute and can also be used as a tool for covert hepatic encephalopathy (CHE) detection, quantification, and follow-up in Taiwan, other Chinese-speaking regions, and many other countries. The diagnostic value of ANT1 and S-ANT1 for CHE were found to be significant, with area under the receiver operating characteristic curve (AUROC) values of 0.807 and 0.786 respectively, and cut-off scores of 18 and 19. ANT1 and S-ANT1 have prognostic value for the first breakthrough of overt hepatic encephalopathy (OHE), number of hospitalization episodes for OHE, and OHE recurrence-free survival, independent of the MELD score. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results